v3.26.1
Note 15 - Segments - Operations by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Sep. 30, 2024
Segment Reporting [Line Items]      
Revenues $ 124,196 $ 149,952  
Cost of revenue 78,441 107,332  
Gross margin 45,755 42,620  
Selling, general and administrative 48,607 59,086  
Research and development 29,199 30,841  
Amortization of intangible assets 18,966 19,861  
Other segment items 18,966 19,861  
Segment operating loss (51,017) (67,168) $ (67,168)
Depreciation and amortization 22,201 23,487  
Cost of Goods and Services Sold 78,441 107,332  
UNITED STATES      
Segment Reporting [Line Items]      
Revenues 83,504 116,207  
IRELAND      
Segment Reporting [Line Items]      
Revenues 9,680 5,480  
CHILE      
Segment Reporting [Line Items]      
Revenues 14,869 14,532  
SPAIN      
Segment Reporting [Line Items]      
Revenues 8,049 6,439  
ISRAEL      
Segment Reporting [Line Items]      
Revenues 0 73  
MEXICO      
Segment Reporting [Line Items]      
Revenues 6,940 6,229  
Other Countries [Member]      
Segment Reporting [Line Items]      
Revenues 1,154 992  
Service [Member]      
Segment Reporting [Line Items]      
Revenues 72,186 102,844  
Cost of revenue 56,143 84,518  
Cost of Goods and Services Sold 56,143 84,518  
Product [Member]      
Segment Reporting [Line Items]      
Revenues 38,042 34,842  
Cost of revenue 22,298 22,814  
Cost of Goods and Services Sold 22,298 22,814  
Transfer of Intellectual Property and Other [Member]      
Segment Reporting [Line Items]      
Revenues 13,968 12,266  
Operating Segments [Member] | Pharmaceutical [Member]      
Segment Reporting [Line Items]      
Cost of revenue 22,298 22,814  
Gross margin 29,712 24,294  
Selling, general and administrative 14,205 12,710  
Research and development 28,753 30,238  
Amortization of intangible assets 16,433 16,111  
Segment operating loss (29,679) (34,765)  
Depreciation and amortization 18,260 17,788  
Cost of Goods and Services Sold 22,298 22,814  
Operating Segments [Member] | Pharmaceutical [Member] | Service [Member]      
Segment Reporting [Line Items]      
Revenues 0 0  
Operating Segments [Member] | Pharmaceutical [Member] | Product [Member]      
Segment Reporting [Line Items]      
Revenues 38,042 34,842  
Operating Segments [Member] | Pharmaceutical [Member] | Transfer of Intellectual Property and Other [Member]      
Segment Reporting [Line Items]      
Revenues 13,968 12,266  
Operating Segments [Member] | Diagnostics [Member]      
Segment Reporting [Line Items]      
Cost of revenue 56,143 84,518  
Gross margin 16,043 18,326  
Selling, general and administrative 26,151 37,956  
Research and development 312 538  
Amortization of intangible assets 2,533 3,750  
Segment operating loss (12,953) (23,918)  
Depreciation and amortization 3,926 5,699  
Cost of Goods and Services Sold 56,143 84,518  
Operating Segments [Member] | Diagnostics [Member] | Service [Member]      
Segment Reporting [Line Items]      
Revenues 72,186 102,844  
Operating Segments [Member] | Diagnostics [Member] | Product [Member]      
Segment Reporting [Line Items]      
Revenues 0 0  
Operating Segments [Member] | Diagnostics [Member] | Transfer of Intellectual Property and Other [Member]      
Segment Reporting [Line Items]      
Revenues 0 0  
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]      
Segment Reporting [Line Items]      
Cost of revenue 0 0  
Gross margin 0 0  
Selling, general and administrative 8,251 8,420  
Research and development 134 65  
Amortization of intangible assets 0 0  
Segment operating loss (8,385) (8,485)  
Depreciation and amortization 15 0  
Cost of Goods and Services Sold 0 0  
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Service [Member]      
Segment Reporting [Line Items]      
Revenues 0 0  
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Product [Member]      
Segment Reporting [Line Items]      
Revenues 0 0  
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Transfer of Intellectual Property and Other [Member]      
Segment Reporting [Line Items]      
Revenues $ 0 $ 0